Budesonide Epimer Control via Isopropyl Ether Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current budesonide production methods struggle to maintain the required epimer A percentage within the 44-51% range due to solubility differences between epimers A and B, affecting the final product's purity and compliance with pharmacopeia standards.
Innovation Solution
A process involving an aqueous hydrochloric acid solution is used to react 16α-hydroxyprednisolone and butyraldehyde, followed by quenching, neutralization, and crystallization in isopropyl ether and methanol to control epimer distribution, ensuring the final budesonide product has 44-51% epimer A.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If crystallization from methanol is performed to purify budesonide, then purity is improved, but epimer A percentage decreases
Solution Approach 1:
The patent changes the crystallization parameters by using isopropyl ether instead of methanol as the crystallization solvent. This parameter change in solvent selection resolves the contradiction because isopropyl ether provides different solubility characteristics that maintain epimer A percentage while achieving purification. The patent explicitly states that crystallization from isopropyl ether allows obtaining budesonide with 44-51% epimer A, avoiding the epimer A loss that occurs with methanol crystallization.
2Manufacturing precision
If multiple crystallizations are performed to increase purity, then purity is improved, but epimer A percentage decreases further
Solution Approach 1:
The patent extracts the problematic methanol crystallization step from the purification process and replaces it with isopropyl ether crystallization. By taking out the harmful crystallization step that selectively removes epimer A, the patent maintains epimer A percentage while still achieving the required purity through the alternative crystallization method.
3Manufacturing precision
If conventional crystallization methods are used, then purification is achieved, but the process requires redefinition and complex purification steps
Solution Approach 1:
The patent makes the isopropyl ether crystallization step serve multiple functions: it simultaneously achieves purification and maintains the desired epimer A percentage (44-51%). This multi-functional crystallization step eliminates the need for separate purification steps and redefinition processes, simplifying the overall manufacturing process while meeting pharmacopeia standards.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves high yields and purity exceeding 90% with controlled epimer ratios, meeting both EU and US pharmacopeia standards without the need for extensive redefinition of purification processes and using only hydrochloric acid as catalyst and solvent.
Implementation Method 1
reacting 16α-hydroxyprednisolone and butyraldehyde within the solution prepared in step a)
Implementation Method 2
quenching the reaction of step b) with water or an aqueous solution
Implementation Method 3
crystallizing from isopropyl ether to obtain crystallized crude budesonide
Implementation Method 4
crystallizing the crystallized crude budesonide with methanol to obtain pure budesonide
Data Source
AI summary
A process is described for preparing budesonide which comprises the steps of: a) preparing an aqueous hydrochloric acid solution; b) reacting 16α-hydroxyprednisolone and butyraldehyde within the solution prepared in step a), in an inert atmosphere; c) quenching the reaction of step b) with water. The process of the invention enables the ratio between the A and B epimers of budesonide to be controlled.